The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
TNF-α in Cancer Treatment: Molecular Insights, Antitumor Effects, and Clinical Utility
Abstract
Learning Objectives: After completing this course, the reader will be able to: Discuss the role of TNF-a in cancer survival and apoptosis.Describe the mechanism of chemotherapy potentiation by TNF-a.Explain the selective targeting of tumor vasculature by TNF-a.Discuss TNFR-1 and TNFR-2 signaling. Access and take the CME test online and receive 1 AMA PRA category 1 credit at CME.TheOncologist.com Tumor necrosis factor alpha (TNF-α), isolated 30 years ago, is a multifunctional cytokine playing a key role in apoptosis and cell survival as well as in inflammation and immunity. Although named for its antitumor properties, TNF has been implicated in a wide spectrum of other diseases. The current use of TNF in cancer is in the regional treatment of locally advanced soft tissue sarcomas and metastatic melanomas and other irresectable tumors of any histology to avoid amputation of the limb. It has been demonstrated in the isolated limb perfusion setting that TNF-α acts synergistically with cytostatic drugs. The interaction of TNF-α with TNF receptor 1 and receptor 2 (TNFR-1, TNFR-2) activates several signal transduction pathways, leading to the diverse functions of TNF-α. The signaling molecules of TNFR-1 have been elucidated quite well, but regulation of the signaling remains unclear. Besides these molecular insights, laboratory experiments in the past decade have shed light upon TNF-α action during tumor treatment. Besides extravasation of erythrocytes and lymphocytes, leading to hemorrhagic necrosis, TNF-α targets the tumor-associated vasculature (TAV) by inducing hyperpermeability and destruction of the vascular lining. This results in an immediate effect of selective accumulation of cytostatic drugs inside the tumor and a late effect of destruction of the tumor vasculature. In this review, covering TNF-α from the molecule to the clinic, we provide an overview of the use of TNF-α in cancer starting with molecular insights into TNFR-1 signaling and cellular mechanisms of the antitumor activities of TNF-α and ending with clinical response. In addition, possible factors modulating TNF-α actions are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Death Receptors: Signaling and Modulation
Ashkenazi, A., & Dixit, V. M. (1998) · Science · doi:10.1126/science.281.5381.1305 · Cited by 5,866
An endotoxin-induced serum factor that causes necrosis of tumors
Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., & Williamson, B. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.9.3666 · Cited by 4,532
Angiogenesis in health and disease
Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,276
Dissemination and growth of cancer cells in metastatic sites
Chambers, A. F., Groom, A. C., & MacDonald, I. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc865 · Cited by 3,911
The TNF and TNF Receptor Superfamilies
Locksley, R. M., Killeen, N., & Lenardo, M. J. (2001) · Cell · doi:10.1016/s0092-8674(01)00237-9 · Cited by 3,650
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
An Essential Role for NF-κB in Preventing TNF-α-Induced Cell Death
Beg, A. A., & Baltimore, D. (1996) · Science · doi:10.1126/science.274.5288.782 · Cited by 3,047
VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia
Gerhardt, H., Golding, M., Fruttiger, M., Ruhrberg, C., Lundkvist, A., Abramsson, A., Jeltsch, M., Mitchell, C., Alitalo, K., Shima, D., et al. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200302047 · Cited by 2,894
Signalling pathways of the TNF superfamily: a double-edged sword
Aggarwal, B. B. (2003) · Nature Reviews Immunology · doi:10.1038/nri1184 · Cited by 2,793
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Old, L. J. (1985) · Science · doi:10.1126/science.2413547 · Cited by 1,895
Openings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
The Tumor Necrosis Factor Ligand and Receptor Families
Bazzoni, F., & Beutler, B. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606273342607 · Cited by 1,225
NF-kB in development and progression of human cancer
Dolcet, X., Llobet, D., Pallares, J., & Matias-Guiu, X. (2005) · Virchows Archiv · doi:10.1007/s00428-005-1264-9 · Cited by 1,169
Identity of tumour necrosis factor and the macrophage-secreted factor cachectin
Beutler, B., Greenwald, D., Hulmes, J. D., Chang, M., Pan, Y.-C. E., Mathison, J., Ulevitch, R., & Cerami, A. (1985) · Nature · doi:10.1038/316552a0 · Cited by 1,131
Degterev, A., Boyce, M., & Yuan, J. (2003) · Oncogene · doi:10.1038/sj.onc.1207107 · Cited by 1,107
Tartaglia, L. A., & Goeddel, D. V. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90116-o · Cited by 1,035
Wang, C.-Y., Cusack, J. C., Liu, R., & Baldwin, A. S. (1999) · Nature Medicine · doi:10.1038/7410 · Cited by 988
Abnormalities in Pericytes on Blood Vessels and Endothelial Sprouts in Tumors
Morikawa, S., Baluk, P., Kaidoh, T., Haskell, A., Jain, R. K., & McDonald, D. M. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64920-6 · Cited by 983
Two tumour necrosis factor receptors: structure and function
Vandenabeele, P., Declercq, W., Beyaert, R., & Fiers, W. (1995) · Trends in Cell Biology · doi:10.1016/s0962-8924(00)89088-1 · Cited by 799
Cellular abnormalities of blood vessels as targets in cancer
Baluk, P., Hashizume, H., & McDonald, D. M. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.005 · Cited by 781
Lienard, D., Ewalenko, P., Delmotte, J. J., Renard, N., & Lejeune, F. J. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.52 · Cited by 719
NF-κB as a therapeutic target in cancer
Orlowski, R. Z., & Baldwin, A. S. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02375-4 · Cited by 553
Modulation of life and death by the TNF receptor superfamily
Baker, S. J., & Reddy, E. P. (1998) · Oncogene · doi:10.1038/sj.onc.1202568 · Cited by 534
Molecular mechanisms of blood vessel formation
Bussolino, F., Mantovani, A., & Persico, G. (1997) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(97)01074-8 · Cited by 470
TNF-Induced Signaling in Apoptosis
Rath, P. C., & Aggarwal, B. B. (1999) · Journal of Clinical Immunology · doi:10.1023/a:1020546615229 · Cited by 462
Eggermont, A. M. M., Koops, H. S., Klausner, J. M., Kroon, B. B. R., Schlag, P. M., Liénard, D., van Geel, A. N., Hoekstra, H. J., Meller, I., Nieweg, O. E., et al. (1996) · Annals of Surgery · doi:10.1097/00000658-199612000-00011 · Cited by 460
Self-citationCloning and expression in Escherichia coli of the gene for human tumour necrosis factor
Shirai, T., Yamaguchi, H., Ito, H., Todd, C. W., & Wallace, R. B. (1985) · Nature · doi:10.1038/313803a0 · Cited by 459
Activation of SAPK/JNK by TNF Receptor 1 Through a Noncytotoxic TRAF2-Dependent Pathway
Natoli, G., Costanzo, A., Ianni, A., Templeton, D. J., Woodgett, J. R., Balsano, C., & Levrero, M. (1997) · Science · doi:10.1126/science.275.5297.200 · Cited by 452
The Distinct Roles of TRAF2 and RIP in IKK Activation by TNF-R1
Devin, A., Cook, A., Lin, Y., Rodriguez, Y., Kelliher, M., & Liu, Z.-G. (2000) · Immunity · doi:10.1016/s1074-7613(00)80194-6 · Cited by 433
Eggermont, A. M., Schraffordt Koops, H., Liénard, D., Kroon, B. B., van Geel, A. N., Hoekstra, H. J., & Lejeune, F. J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2653 · Cited by 398
Self-citationDual role of tumor necrosis factor-alpha in angiogenesis.
Fajardo, L. F., Kwan, H. H., Kowalski, J., Prionas, S. D., & ALLISON, A. C. (1992) · PubMed · Cited by 355
NF-κB in cancer: a marked target
Lin, A., & Karin, M. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00128-1 · Cited by 355
Muppidi, J. R., Tschopp, J., & Siegel, R. M. (2004) · Immunity · doi:10.1016/j.immuni.2004.10.001 · Cited by 338
Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-κB
Ganster, R. W., Taylor, B. S., Shao, L., & Geller, D. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151239498 · Cited by 321
Tumor necrosis factor, cancer and anticancer therapy
MOCELLIN, S., ROSSI, C., PILATI, P., & NITTI, D. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.11.001 · Cited by 311
Tumor Necrosis Factor: Function, Release and Clearance
Bemelmans, M. H. A., van Tits, L. J. H., & Buurman, W. A. (1996) · Critical Reviews™ in Immunology · doi:10.1615/critrevimmunol.v16.i1.10 · Cited by 271
IFNγ sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway
Fulda, S., & Debatin, K.-M. (2002) · Oncogene · doi:10.1038/sj.onc.1205255 · Cited by 260
Nauts, H. C., FOWLER, G. A., & Fh, B. (1953) · PubMed · Cited by 247
Clinical applications of TNF-α in cancer
Lejeune, F. J., Rüegg, C., & Liénard, D. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80226-4 · Cited by 243
MARMENOUT, A., FRANSEN, L., TAVERNIER, J., VAN DER HEYDEN, J., TIZARD, R., KAWASHIMA, E., SHAW, A., JOHNSON, M., SEMON, D., MÜLLER, R., et al. (1985) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1985.tb09226.x · Cited by 239
Toxic effect of tumor necrosis factor on tumor vasculature in mice.
Watanabe, N., Niitsu, Y., Umeno, H., Kuriyama, H., Neda, H., Yamauchi, N., Maeda, M., & Urushizaki, I. (1988) · PubMed · Cited by 237
Current uses of isolated limb perfusion in the clinic and a model system for new strategies
Eggermont, A. M., de Wilt, J. H., & ten Hagen, T. L. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01141-0 · Cited by 235
Self-citationImproving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration
Curnis, F., Sacchi, A., & Corti, A. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215223 · Cited by 228
Müller, U., Jongeneel, C. V., Nedospasov, S. A., Lindahl, K. F., & Steinmetz, M. (1987) · Nature · doi:10.1038/325265a0 · Cited by 225
Fraker, D. L., Alexander, H. R., Andrich, M., & Rosenberg, S. A. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.2.479 · Cited by 213
de Wilt, J. H. W., ten Hagen, T. L. M., de Boeck, G., van Tiel, S. T., de Bruijn, E. A., & Eggermont, A. M. M. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1032 · Cited by 207
Self-citationPG490 (Triptolide) Cooperates with Tumor Necrosis Factor-α to Induce Apoptosis in Tumor Cells
Lee, K. Y., Chang, W.-T., Qiu, D., Kao, P. N., & Rosen, G. D. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.19.13451 · Cited by 184
Identity of differentiation inducing factor and tumour necrosis factor
Takeda, K., Iwamoto, S., Sugimoto, H., Takuma, T., Kawatani, N., Noda, M., Masaki, A., Morise, H., Arimura, H., & Konno, K. (1986) · Nature · doi:10.1038/323338a0 · Cited by 182
Cytostatic and cytotoxic activity of tumor necrosis factor on human cancer cells.
Ruggiero, V., Latham, K. M., & Baglioni, C. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.8.2711 · Cited by 152
Veen, A. H. V. D., de Wilt, J. H. W., Eggermont, A. M. M., van Tiel, S. T., Seynhaeve, A. L. B., & ten Hagen, T. L. M. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1027 · Cited by 150
Self-citationLimb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-α be better?
Bonvalot, S., Laplanche, A., Lejeune, F., Stoeckle, E., Pechoux, C. L., Vanel, D., Terrier, P., Lumbroso, J., Ricard, M., Antoni, G., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi229 · Cited by 134
Grünhagen, D. J., Brunstein, F., Graveland, W. J., van Geel, A. N., de Wilt, J. H. W., & Eggermont, A. M. M. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000146147.89667.ed · Cited by 126
Self-citationSchwarz, M. A., Kandel, J. J., Brett, J., Li, J., Hayward, J., Schwarz, R. E., Chappey, O., Wautier, J., Chabot, J. A., Gerfo, P. L., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.341 · Cited by 125
NF-κB-dependent MnSOD expression protects adenocarcinoma cells from TNF-α-induced apoptosis
Delhalle, S., Deregowski, V., Benoît, V., Merville, M., & Bours, V. (2002) · Oncogene · doi:10.1038/sj.onc.1205489 · Cited by 125
Bradley, J. R., Thiru, S. S., & Pober, J. S. (1995) · PubMed · Cited by 115
Olieman, A. F. T. (1999) · Archives of Surgery · doi:10.1001/archsurg.134.3.303 · Cited by 111
Recombinant human tumor necrosis factor‐α: Thrombus formation is a cause of anti‐tumor activity
Shimomura, K., Manda, T., Mukumoto, S., Kobayashi, K., Nakano, K., & Mori, J. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910410215 · Cited by 106
Totzke, G., Schulze‐Osthoff, K., & Jänicke, R. U. (2003) · Oncogene · doi:10.1038/sj.onc.1206837 · Cited by 100
Nooijen, P. T. G. A., Manusama, E. R., Eggermont, A. M. M., et al. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.652 · Cited by 86
Self-citationLejeune, F. J., Liénard, D., Leyvraz, S., & Mirimanoff, R. (1993) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80163-7 · Cited by 81
Role of SODD in Regulation of Tumor Necrosis Factor Responses
Takada, H., Chen, N., Mirtsos, C., Suzuki, S., Suzuki, N., Wakeham, A. C., Mak, T. W., & Yeh, W. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.11.4026-4033.2003 · Cited by 71
Grünhagen, D. J., de Wilt, J. H. W., Graveland, W. J., van Geel, A. N., & Eggermont, A. M. M. (2005) · Cancer · doi:10.1002/cncr.21547 · Cited by 67
Self-citationvan Etten, B., van Geel, A. N., de Wilt, J. H. W., & Eggermont, A. M. M. (2003) · Annals of Surgical Oncology · doi:10.1245/aso.2003.03.076 · Cited by 66
Self-citationBinder, C. R., Schulz, M., Hiddemann, W., & Oellerich, M. (1999) · PubMed · Cited by 65
ten Hagen, T. L. M., Seynhaeve, A. L. B., van Tiel, S. T., Ruiter, D. J., & Eggermont, A. M. M. (2001) · International Journal of Cancer · doi:10.1002/ijc.1578 · Cited by 65
Self-citationTumor necrosis factor: molecular and cellular biology and clinical relevance
Billett, M. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)80221-1 · Cited by 59
Grünhagen, D. J., van Etten, B., Brunstein, F., Graveland, W. J., van Geel, A. N., de Wilt, J. H. W., & Eggermont, A. M. M. (2005) · Annals of Surgical Oncology · doi:10.1245/aso.2005.03.060 · Cited by 58
Self-citationLans, T. E., Grünhagen, D. J., de Wilt, J. H. W., van Geel, A. N., & Eggermont, A. M. M. (2005) · Annals of Surgical Oncology · doi:10.1245/aso.2005.03.093 · Cited by 54
Self-citationvan Etten, B., de Vries, M. R., van Ijken, M. G. A., Lans, T. E., Guetens, G., Ambagtsheer, G., van Tiel, S. T., Boeck, G. D., de Bruijn, E. A., Eggermont, A. M. M., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600707 · Cited by 50
Self-citationTumor necrosis factor: Molecular and cellular biology and clinical relevance
(1995) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(95)90011-x · Cited by 45
Hoving, S., Brunstein, F., de Wiel‐Ambagtsheer, G. A., van Tiel, S. T., Boeck, G. D., de Bruijn, E. A., Eggermont, A. M. M., & ten Hagen, T. L. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2214 · Cited by 41
Self-citationRossi, C. R., D, S. M. M., Pilati, P., D, M. F. M., Campana, L. G., Quintieri, L., Salvo, G. L. D., & Lise, M. (2005) · Annals of Surgical Oncology · doi:10.1245/aso.2005.12.038 · Cited by 40
D, S. M. M., Provenzano, M., Rossi, C. R., Pilati, P., Scalerta, R., Lise, M., & Nitti, D. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0791 · Cited by 19
Cited by
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Tumor targeting via EPR: Strategies to enhance patient responses
Golombek, S. K., May, J.-N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.007 · Cited by 1,262
Cytokines in clinical cancer immunotherapy
Berraondo, P., Sanmamed, M. F., Ochoa, M. C., Etxeberria, I., Aznar, M. A., Pérez-Gracia, J. L., Rodríguez-Ruiz, M. E., Ponz-Sarvise, M., Castañón, E., & Melero, I. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0328-y · Cited by 1,205
Biogenic synthesis of nanoparticles: A review
Sharma, D., Kanchi, S., & Bisetty, K. (2019) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2015.11.002 · Cited by 948
Applications of gold nanoparticles in cancer nanotechnology
Cai, W. (2008) · Nanotechnology, Science and Applications · doi:10.2147/nsa.s3788 · Cited by 851
Metadata
- Authors
- van Horssen, R., ten Hagen, T. L. M., & Eggermont, A. M. M.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-04-01
- Volume
- 11
- Issue
- 4
- Pages
- 397-408
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2153161557
- Cited by
- 701
- References
- 76
- FWCI
- 9.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.